anti-hu/mo VEGFR-1/Flt-1, Antagonistic monoclonal antibody Anti-Hu/Mo 100 µg,Reliatech,mV1004.1m-h-m

This antibody was produced from a hybridoma (mouse myeloma fused with spleen cells from a mouse immunized with purified extracellular domain of recombinant human VEGFR1.

Host

Mouse

Reactivity

Human, Mouse

Application

WB, Blocking

Platform ID

BAB501694917

Reliatech

Headquarters

Lindener Straße 15 38300 Wolfenbüttel Germany

Contact

Tel: +49 (0) 5331 - 8586987
Fax: +49 (0) 5331- 8586989

Product Specifications
Scientific Background
Synonyms

Specifications

Nameanti-hu/mo VEGFR-1/Flt-1, Antagonistic monoclonal antibody Anti-Hu/Mo 100 µg
Cat. No.mV1004.1m-h-m
Accession NumberP17948
HostMouse
IsotypeIgG1
ReactivityHuman, Mouse
ApplicationWB, Blocking
Working DilutionsWB: 1:400-1000
Clone Number(#MAB0702)
Appearance/Formlyophilized
FormulationPBS
ReconstitutionCentrifuge the vial prior to opening. Reconstitute the antibody with 200 µl sterile PBS and the final concentration is 500 µg/ml.
StorageLyophilized samples are stable for 2 years from date of receipt when stored at -20°C. Reconstituted antibody can be aliquoted and stored frozen at < -20°C for at least six months without detectable loss of activity.
Regulatory StatusFor research use only

Scientific Background

Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. The antibody will bind near the ligand binding site of the receptor and has antagonistic activity by blocking the binding of natural ligands.

Synonyms

vascular endothelial growth factor receptor-1; FLT1; FLT; VEGF receptor 1

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.